FGF19 and Pruritus: By avoiding enterohepatic circulation, cilofexor primarily targets intestinal FXR receptors to stimulate fibroblast growth factor 19 (FGF19) release while avoiding systemic side effects such as pruritus, hyperlipidemia, and hepatotoxicity (Figure 3).